News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Argenta Discovery Inc. Announces Record Year For Peer-Reviewed Publications

12/9/2013 10:05:59 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Harlow, UK, 09 December 2013 – Argenta, a Galapagos NV (Euronext: GLPG) company that provides drug discovery services from target validation to proof of concept, has announced that 2013 has seen a record number of peer-reviewed publications featuring its scientists as co-authors with its clients and collaborators. The 2013 total of 15 publications surpasses the previous record of 13 achieved in 2007. The publications have been co-authored with clients such as Genentech, AstraZeneca and Corcept and include papers in such prestigious journals as Nature and Proceedings of the National Academy of the USA. Details of these, and other Argenta publications, can be found on the company’s website:

Dr John Montana, Managing Director of Argenta, commented, “Argenta stands or falls by the quality of the science that it conducts for and together with its clients. This record number of publications in high-quality, peer-reviewed scientific journals is another indication of the scientific prowess of Argenta’s industry-experienced staff and the success that we have achieved in partnership with our clients”.

A further indication of Argenta’s strength in drug discovery is the 40 development compounds that it has delivered on behalf of its clients during the 13 years since its inception. The clinical progress of some of these can be seen on the company’s website:

About Argenta

Argenta is a fully-integrated drug discovery services provider and a trusted partner for many world-leading pharmaceutical and biotechnology companies including AstraZeneca, Genentech, Janssen and Zafgen.

Argenta combines a comprehensive range of discovery services with multiple disease area expertise including respiratory, oncology, pain and inflammatory disease, providing a compelling combination of scientific excellence, a full in vitro and in vivo pharmacology and DMPK capability, cutting edge medicinal chemistry thinking and cost-effectiveness.

Argenta provides fully-integrated and stand-alone services from target validation through to Development Candidate nomination and have built an Industry-leading track record of delivering development compounds, averaging over three development compounds per year.

Founded in 2000, Argenta currently employs over 160 scientists in the UK with an average of 17 years’ pharmaceutical drug discovery expertise. Argenta has delivered 40 development candidates in 13 years, and greater than 85% of the Company’s contract research is repeat business. More information at:


Media contact

Lorna Cuddon

Zyme Communications

Tel: +44 7811996942



John Montana

Managing Director, Argenta

Tel. +44 1279 645645


Help employers find you! Check out all the jobs and post your resume.

Read at

comments powered by Disqus